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Healthcare prioritisation at the local 
level: a socio-technical approach 
 
Abstract 
Cost effectiveness analysis is a systematic tool to inform resource allocation decision in 
healthcare. There is extensive evidence, however, that the tool is difficult to apply in practice, 
particularly at the level of local health planners, because it is not accessible to those involved 
in the prioritisation process and not embeds assumptions which are felt to be unacceptable 
for ethical or other reasons. Pragmatic tools such as Program Budgeting and Marginal 
Analysis appear to be more suitable for supporting local decisions by engaging stakeholders 
in a deliberative process. Unlike cost-effectiveness analysis, however, these tools are hard to 
relate to widely accepted health economic principles. This paper presents a socio-technical 
approach which draws explicitly on health  economic theory and in a practical and 
reproduceable way through an action research case study with a local healthcare planner of 
the English National Health Service. Through close and iterative work with those responsible 
for allocating resources we present a formal model to capture the objectives of the health 
planners, a communicative procedure and interactive elicitation methods to help key 
stakeholders to articulate their knowledge and values. The approach proved accessible and 
acceptable and has been used in making spending decisions.  
1.  Introduction 
One of the central aims of health economics as a discipline is the development of methods for the 
prioritisation of healthcare resources in a way which is justifiable with respect to normative 
principles and incorporates evidence about health and healthcare performance.  However, 
methods also have to be practical and what counts as practical depends on the level at which 
prioritisation takes place.  For example, in the English National Health Service (NHS) over the 
last few years, at least two levels can be distinguished.  At the national level priorities are 
expressed through national policies which lay out standards of care and good practice guidelines.  
However, it is at the local level that decisions about contracting particular services are made, and 
it is these decisions which determine, in the most direct and tangible sense, how much, what and 
what sort of care patients resident in the locality receive.  System actors at these different levels 
have quite different needs and competencies, and hence may require different processes for 
setting priorities. 
 
The most widely accepted framework for healthcare prioritisation, at least within the health 
economic community, is Cost Effectiveness Analysis or CEA (Drummond, Sculpher, Torrance, 
O' Brien, & Stoddart, 2005; Gold, Siegel, Russell, & Weinstein, 1996).  The precise usage of this 
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term is somewhat contested, but considered in its broadest sense, the key idea of CEA is that 
decisions about which particular programmes to fund should be made on the basis of (or at least 
meaningfully informed by) a comparative analysis of the costs of those programmes, and the 
quantum of health which those programmes deliver, and to whom.  Within the mainstream of 
health economics orthodoxy, the quantum of health is generally measured in Quality Adjusted 
Life Years or QALYs, and the focus is traditionally on the marginal beneficiary (Williams, 1985).   
 
A subject of some controversy in the area in recent years has been the role of the methods of the 
World Health Organisation, so-called “Generalised Cost Effectiveness Analysis” (Tan-Torres 
Edejer, Baltussen, Adam, Hutubessy, Acharya, Evans et al., 2003).  Two features of this 
generalised approach stand out: one is the use of the DALY (Disability-Adjusted Life Year) 
instead of the QALY metric, and the other is a stress on taking the population perspective, rather 
the perspective of the marginal beneficiary  We consider the DALY metric to be problematic for 
technical reasons (Airoldi & Morton, 2009), but we also take a population focus.  As we argue 
below this allows decision makers to have a sense of the cost impact of implementing change and 
the opportunity costs when operating out of a fixed budget envelope – something which applying 
a simple cost-effectiveness cut-off rule does not do (Birch & Gafni, 2006; Gafni & Birch, 2006). 
 
Despite the existence of standards to perform CEA laid out in the above cited texts, there is a gap 
between technical analyses and their use to design policy recommendations both at the national 
and local levels, but particularly at the local level.  
 
At the national level, where CEA is relatively widely applied, Bryan and colleagues (Bryan, 
Williams, & McIver, 2007; Williams & Bryan, 2007), offer a general characterisation of barriers 
to the use of CEA in terms of “accessibility” and “acceptability” based on interviews, committee 
observations and document analysis of the Appraisals Committee, the Health Technology 
Assessment agency of the English NHS. These authors claim that accessability is compromised 
because of the difficulties of interpreting the results of CEA because of the lack of health 
economic skills of individual members of the committee, lack of timely access to data underlying 
the analysis and results presented too technically, making it difficult for non health-economists to 
fully appreciate their meaning and robustness. The acceptability of CEA is limited because of the 
inability of the Quality Adjusted Life Year (QALY) tool to account for benefits which are valued 
by patients (e.g. an issue identified by NICE Appraisal Committee was the difficulty to account 
for disease irreversibility); the lack of a standard, systematic way to account for the impact of 
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interventions on health inequality which the committee could apply consistently across different 
evaluations; and concerns over the implicit consideration of the opportunity cost of recommended 
interventions through the use of a threshold cost-effectiveness value, over which interventions are 
deemed cost-ineffective and should not be funded.  
 
At the local level the problems of acceptability and accessibility are exacerbated by the even 
scarcer availability of time and resources to commission CEA, and the specialist skills to interpret 
it.  Moreover, the local environment is more constrained than the national environment, as local 
prioritisation must take place within a framework of budgets and political objectives which are 
exogenously determined and imposed on the local organisation (Eddama & Coast, 2008).  
 
One approach that has been proposed and used extensively to facilitate systematic planning at the 
local level is Program Budgeting and Marginal Analysis (PBMA; Madden, Hussey, Mooney, & 
Church, 1995; Mitton & Donaldson, 2001; Mitton & Donaldson, 2004; Mitton, Patten, Waldner, 
& Donaldson, 2003; Mooney, 1978; Peacock, Mitton, Ruta, Donaldson, Bate, & Hedden, 2010; 
Peacock, Richardson, Carter, & Edwards, 2007). PBMA is a pragmatic approach to applying the 
economic principles of marginal analysis and opportunity cost to local resource allocation 
decisions. In PBMA a structured process is used to engage local stakeholders in considering 
current spend, and proposing a ‘wish list’ of new interventions and a ‘hit list’ of potential 
disinvestments from current activity to fund the new proposals. The value of current and new 
interventions is generally assessed against all the criteria considered relevant by the local 
stakeholders using Multi-Criteria Decision Analysis (MCDA; Keeney & Raiffa, 1976) and 
participants are invited to consider the impact of changes to healthcare provision, that is the 
difference in benefits between funding the interventions on the wish list or on the hit list.  
However, contrary to CEA, it is not clear how the criteria proposed within PBMA relate to the 
normative principles, of health economics, nor it it clear how epidemiological and clinical 
evidence can be integrated into the modelling in a way consistent way. 
 
This paper contributes to the development of methods to inform resource allocation by local 
healthcare planners proposing a “socio-technical” approach. The term “socio-technical” emerged 
around the 1960s to refer to an approach to designing organisational change in the workplace 
which recognised the need to take into account simultaneously the people and technology 
dimensions of the work environment (Trist, 1981).  More broadly, the term can be understood as 
applying to approaches which consider simultaneously a social dimension, e.g. engaging 
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stakeholders in defining and solving a problem, and a technical dimension, e.g. the rational-
analytic method which could be applied to quantify and solve the problem at hand (Phillips, 2007; 
Phillips & Bana e Costa, 2007).  The use of a socio-technical approach seems appropriate in the 
context of healthcare systems, which are characterised by a natural tension which arises from the 
need to reconcile policy-making as both a political process with policy-making and an analytical-
rational process based on expertise (Klein, 2006). 
 
The paper presents a case study to describe the development and application of a socio-technical 
approach. Section two describes the research methods. Section three presents the case study in 
terms of context, terms of reference, the socio-technical process (formal analysis, communication 
procedure and interactive elicitation methods) and results. Section four discusses the accessibility, 
acceptability and the impact of the approach and section five provides concluding remarks. 
2.  Methods 
This paper employs action research and the case study methodology. The term action research 
covers a multitude of activities and methods; their common feature is the participative 
engagement of the subjects of the analysis in the research, the research objective of analysing the 
world and trying to change it at the same time (Eden & Huxham, 1996). The case study 
methodology illuminates the set of decisions taken by the health planners in terms of why and 
how they were taken (Yin, 2009).   
 
The research was conducted in collaboration with and for the Isle of Wight Primary Care Trust 
(PCT) of the English National Health Service (NHS) in 2008.  PCTs are responsible for designing 
contracts with providers defining the type and volume of activity they expect to purchase to meet 
the health need of the local population of about 330,000 people on average. As the local planning 
and purchasing agency of the NHS, PCTs are funded through general taxation and a capitation 
formula (Department of Health, 2008).  
 
The approach we took to helping the organisation prioritise was a decision analysis approach. 
Decision analysis aims at assisting ‘decision makers’ to make better decisions by dividing a 
complex problem in its simpler elements, analysing these separately, and re-combining them 
according to a valid theory (Raiffa, 1968). The use of decision analysis to assist with problems of 
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prioritisation or choice of a portfolio of multiple items to fund, is sometimes referred to “Portfolio 
Decision Analysis” as opposed to the simpler and more traditional setting where the decision 
maker has to choose one item out of a set (Salo, Keisler, & Morton, 2011).   
 
The approach was organised around evaluation workshops with stakeholders which took the form 
of ‘Decision Conferences’. Decision Conferencing (DC), like PBMA, is a deliberative process. 
An impartial facilitator works iteratively with key stakeholders to generate a formal, ‘requisite’ 
model to assess options on multiple objectives using MCDA and generate a summary benefit 
score (Phillips & Bana e Costa, 2007).  A model is ‘requisite’ when it is sufficient to represent the 
mental models, beliefs about uncertainty and preferences of the participants and additional model 
refinements do not generate new insights in the problem (Phillips, 1984). The various authors had 
somewhat different roles in the implementation of the approach, and in the ensuing, authors will 
be referred to by their initials (MA, AM, JS, RGB).  
 
The analysis is based on extensive field notes, which include: the chronological development of 
the stakeholder engagement process and of the prioritisation technique, comments and reflections 
on these developments of the Strategic planning group, semi-structured and unstructured 
interviews with clinical staff and PCT managers, email correspondence with PCT staff, direct 
observation of workshops, flipcharts produced by workshop participants, clarification questions 
and comments received on the report summarising the results of the analysis.    
3.  Case study 
Organisational context and term of reference 
The Isle of Wight NHS PCT is located on an Island off the South-East coast of England and has a 
population of about 140,000. The PCT is comparatively small and, in contrast to elsewhere in 
England, it is organised as an integrated healthcare system with both purchasing and provision 
responsibilities, but with governance arrangements to ensure separation of responsibilities.   
 
The project was formally launched when JS presented her annual Public Health Report to the 
NHS Board; and identified five key priority areas to focus on to reduce mortality and improve 
quality of life: cardiovascular disease, cancer, respiratory condition, mental and children health. 
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During the same meeting MA illustrated the process of DC and gained support from the Board to 
use this in developing their commissioning strategy.  The aims of the engagement were to involve 
local stakeholders in the five identified priority areas to generate a robust plan for allocating an 
additional £1m on a recurrent basis from 2008 to 2012 through the PCT ‘operational plan’ (i.e. 
the budgeting or purchasing plan), on a value for money basis. The Board recommended looking 
at costs and using three criteria to identify value: to increase health (both in terms of reduced 
mortality and increased quality of life), to reduce health inequalities, and to be operationally and 
politically feasible. 
The socio-technical process  
The action research project ran from April to November 2008. This time corresponded with the 
process leading up to the operational plan proposal. The engagement consisted in (i) a schedule of 
meetings (two initial meetings in the spring and then fortnightly from June); (ii) the design, in 
collaboration with the PCT, of a social process to engage key stakeholders (including managers, 
clinicians, patients and public representatives) and of a technical process based in CEA principles 
to derive a list of priorities to allocate the growth money; (iii) the guidance on extracting 
information from available demographic and epidemiological data to support the evaluation of 
different interventions; (iv) the facilitation of meetings with stakeholders; (v) the analysis of 
results; (vi) the production of a report to document the process and to identify recommendations 
from the analysis; and answering further questions and and performing supplementary analyses. 
 
Executive level leadership was provided through the Strategic Planning group, which was set up 
by the Director of Public Health and Chief Medical Adviser of the Island (JS) with the support of 
the PCT board. They met fortnightly under the chairmanship of JS who also proposed and 
circulated for comments an agenda in advance. The group consisted of all eight executive 
directors; MA and a secretary also attended meetings. Its responsibility was to design an 
engagement process, choose a prioritisation technique and put forward recommendations to invest 
available, additional resources.  
 
The Strategic Planning group selected and engaged stakeholders in two different types of event. 
First, they organised separate workshops for each of the five priority areas asking lead 
commissioners responsible for those areas to draw a list of key stakeholders including acute and 
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community care clinicians, council representatives, voluntary sector representatives, nurses, 
public and patients’ representatives, managers of the hospital and the ambulance service. The 
cardiovascular area was divided in the two subcategories of coronary heart disease and stroke, 
which were led by different commissioning managers. 
 
The six stakeholder workshops followed a similar structure. They were two-hour meetings, co-
chaired by one executive director and the lead commissioner responsible for the area, and 
facilitated by MA (with the exception of the workshop on Children, which was facilitated by JS.). 
The mix of invited stakeholders aimed to represent the diverse perspectives which the 
commissioners wished to consider in allocating resources. The number of participants varied 
between 10 and 30 (a total of about 100 people were consulted in total) and the facilitation aimed 
at airing all perspectives. To support the discussion, basic demographic and epidemiological data 
on the disease area produced by the PCT analyst were provided. The workshops identified the key 
issues in each area and put forward a total of twenty-one strategic initiatives to improve quality of 
life and reduce health inequalities on the Island to be formally evaluated in the Decision 
Conference and prioritised the allocation of the available £1m of additional resources. Some 
people from each group volunteered to collect further information to give a clearer picture of their 
proposed initiatives. The total cost of the initiatives to be prioritised was over £5m. 
 
The lead commissioners summarised the proposed initiatives in their area according to a common 
template requiring them to define the intervention operationally (e.g. to hire two health visitors in 
defined locations), to assess its expected cost, to estimate the number of people who would 
benefit, to describe the ‘average’ beneficiary (by demographic information, severity of the 
condition and socio-economic background in order to reflect on the impact on health inequalities) 
and to describe qualitatively or quantitatively the health benefit to the intended beneficiaries, and 
their families and carers.  
 
The issues and interventions emerging from the workshops were reviewed in a one-day Decision 
Conference attended by 25 key stakeholders facilitated by MA with the support of AM. The 
meeting ran from 9.30 to 16.45 with a brief introduction, discussion in separate groups according 
to disease areas in the morning, plenary discussion and analysis of the results in the afternoon. 
The key stakeholders were the eight executive directors of the PCT, nine commissioning 
managers, three patients and public representatives, four clinical experts and one representative of 
social services. 
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In the meeting, participants built a formal model of the costs and value of all twenty-one strategic 
interventions on-the-spot in terms of costs and the three criteria defined by the Strategic planning 
group as follows: 
 Costs (c): The additional annual funding required in 2009 and 2010 both to set-up and to 
run the intervention, in £’000. Set-up costs included initial investments such as training 
and equipment and the running costs included costs such as personnel. 
 Health benefit to the Isle of Wight population (N*B): the extent to which the assessed 
additional intervention would improve the quality (and length) of life of those who 
benefit. The health benefit was modelled as the product of: 
o the number (N) of patients who benefit (excluding carers/family) by funding this 
additional intervention; 
o the potential benefit (B) in quality (and length) of life from this additional 
intervention, assuming successful implementation, to the ‘average’ patient who 
benefits,  including the benefit to his/her carers/family and taking into account 
the timing and duration of those benefits. 
 Health inequalities (I): the extent to which this additional intervention has the potential 
for reducing both differences in access and differences in health outcomes (across 
geographical areas, between men and women, of special groups) if appropriately 
targeted. 
 Feasibility (p): Probability of success (from 0% to 100%) to achieve the assessed 
benefits, assuming funding is granted and taking into account: ease of implementation; 
availability of workforce; acceptability to stakeholder/environment (e.g. willingness to 
make this change happen); process complexity (e.g. number of steps required). This 
criterion captures the concept of ‘operationally and politically feasible’ the Board asked  
the Strategic Planning group to consider in its terms of reference.  
 
The formal model underpinning the evaluation is to Max Σj E(vj) * xj, where E() indicates an 
expected value calculation, vj is the benefit from intervention j (details of its calculation will be 
provided later), and xj is an index variable with value 1 in case intervention j is funded, and value 
0 in case it is not. In the model used during the workshop, we made a simplifying assumption 
about E(), namely we assumed that the intervention would have been successful and deliver its 
benefits in full with probability p%; if unsuccessful (1-p% probability), it would have delivered 
no benefit. This assumption was subjected to sensitivity analysis after the stakeholder event. The 
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formal model and its notation were hidden to workshop participants, who were presented with 
simpler, accessible visual aids for each step of the process, which will be described below. The 
budget constraint was not modeled explicitly because the PCT had some flexibility on allocating 
resources in the current and the subsequent year. The aim of the technical model was hence to 
generate a priority list of the twenty one interventions in terms of their cost-effectiveness or 
Value-for-Money and to agree the exact amount of available budget after the analysis. 
 
To inform the evaluation, each participant drew on a copy of the templates describing the 
interventions proposed by the six stakeholder workshops, background demographic and 
epidemiological information on the local population, a handout with the operational definition of 
the assessment criteria and, of course, their individual expert knowledge. Through facilitated 
discussion and challenge, participants assessed each intervention following a systematic three-
step process.  
 
First, participants revised the information provided by the lead commissioners and scored the 
options for each separate commissioning group g=1,…,6 (which corresponded to the six 
stakeholders’ groups), one criterion at a time as illustrated in Table 1, which reports the 
assessment for the three proposed interventions by the commissioning lead for cancer services, 
who also commissioned all palliative care. This required: 
 Validating the number N of people who benefit (using demographic and epidemiological 
statistics, data on hospital admissions and expert judgment).  
 Providing a description of the ‘average’ beneficiary of the proposed intervention and 
agreeing a qualitative description of the expected benefit (derived from clinical evidence 
of effectiveness and expert judgments). 
 Quantifying the health benefits B to beneficiaries attributable to action within the budget 
period (over the beneficiaries’ lifetime, assuming successful implementation and 
compliance). This assessment was informed by evidence (e.g. QALY gains) whenever 
available. Due to time constraints and the exploratory nature of this approach, we used 
direct rating with a Visual Analogue Scale (VAS) technique (Parkin & Devlin, 2006; von 
Winterfeldt & Edwards, 1986) on the basis of the evidence brought to bear by clinical 
experts attending the meeting as follows: participants identified the option providing the 
greatest individual health benefit which was assigned a score of 100; they then scored the 
remaining interventions relative to this benchmark score of 100 and a fixed benchmark of 
0 corresponding to ‘no additional health benefits compared to current care’. A rectangle 
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summarised the population health impact N*B visually (Figure 1), with the numbers who 
benefit on the horizontal axis and the average benefit per person on the vertical axis. The 
area of the rectangle is the expected overall benefit of the intervention in the population.  
 Assessing the impact on reducing health inequalities I on a VAS. Interventions which had 
no impact on health inequalities were given a score of zero. Participants identified the 
option with the greatest potential to reduce health inequalities (assuming successful 
implementation and compliance); this was assigned a score of 100 and the remaining 
options scored relative to this benchmark.  
 Assessing the operational and political feasibility of the option by asking participants 
their degree of belief that it would deliver the stated benefits in probabilistic terms p (with 
100% representing absolute confidence). 
 
In case of disagreement, participants explored the reasons and sought a consensus view, which 
was usually reached. If a consensus view could not be arrived at, the range of proposed values 
was recorded for sensitivity analysis purposes and the majority’s view at the end of the discussion 
used for the base model. 
Table 1 Example of template and scores: options for cancer (a similar template was used for 
each of the other four priority areas and their eighteen interventions) 
Initiative [j] 
No. 
who 
benefit 
per 
year 
[Nj] 
‘Average’ 
beneficiary 
Description of individual 
benefit compared to 
current care 
Health 
benefit 
per 
person 
score 
[Bj] 
Health 
inequality 
reduction 
score [Ij] 
Feasibility 
(Probability 
of success) 
[pj] 
Early 
detection & 
diagnosis in 
cancer 
200 
Person in her/his 
mid-60s, more 
likely to be 
female and from 
“hard to reach” 
groups in society 
Earlier diagnosis is 
associated with better 
prognosis (we assume no 
benefit for people 
screened and with 
negative results) 
100 100 95% 
Palliative & 
End of Life 
care (all 
diseases) 
1,500 
Person in her/his 
late 70s, with life 
limiting long 
term health 
condition, equally 
likely to be from 
any socio-
economic groups 
Benefits to 
carers/family/friends. 
Benefits to patient: no 
change in life expectancy 
but a better quality of life 
in its last months 
75 50 70% 
Relocation 
of active 
treatment 
in cancer 
300 
Person in her 
mid-60s, more 
likely to be 
female; extremely 
severe illness 
Patients are already 
receiving this treatment 
off the island, but there 
are psychological benefits 
of providing the service 
locally 
25 0 10% 
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Figure 1 The rectangles of health benefit to the population for the three proposed initiatives in 
Cancer. Similar rectangles were drawn for each of the five areas and their interventions. 
 
 
Second, the facilitators used decision analysis techniques to convert the scores on the three 
criteria on a common metric using three vectors of weights (Goodwin & Wright, 2004), which 
were elicited from participants. With the first vectors of weights,  1 6( ,..., ,..., )B B B Bgw w w w=  and 
1 6( ,..., ,..., )I I I Igw w w w= , participants considered one objective or criterion at a time and assessed 
the relative contribution to achieving the given objective by investing in a set of interventions in a 
disease group g (e.g. all proposed initiatives in the Cancer area) compared to another (e.g. all 
proposed initiatives in the Respiratory one). These weights are rescaling factors to convert scores 
for the same criterion in different disease areas on a common scale. We elicited a total of twelve 
within-criteria weights assigning a weight of 100 to the highest Bgw  and the highest 
I
gw . Then 
participants considered health benefit and inequality reduction criteria and assessed their relative 
contribution to achieve the PCT’s objectives, to convert scores on different criteria on a common 
value scale. To elicit this weight, participants considered the disease areas which received the 
highest within criteria weights of 100. A single rescaling factor W was sufficient to render scores 
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on the health inequality criterion commensurable with scores on the health benefit cirterion. The 
judgments expressed in the across criteria weights are inherently subjective and the weighting 
procedure is cognitively complex and emotionally challenging. The facilitator helped participants 
in forming and expressing these values openly, noting uncertainty and disagreements to be 
explored by sensitivity analysis. 
 
To incorporate the feasibility criterion, in the Decision Conference it was assumed that the PCT 
would not achieve any benefit from an unsuccessful intervention (for each intervention j this 
occurs with probability 1-pj%). After the meeting, extensive parametric sensitivity analysis tested 
the robustness of results to this assumption through a parameter k∈[0,1], which represented the 
proportion of benefits which would have been achieved in case of unsuccessful interventions. 
Defining ( )g j as the commissioning group of intervention j, the expected value of each 
intervention was hence calculated as follows (assuming k=0 during the Decision Conference): 
 
( ) ( ) ( )( ) ( ) ( ) ( )(1 )B I B Ij j g j j j g j j j g j j j g j jE v p w N B W w I p k w N B W w I = ⋅ ⋅ ⋅ + ⋅ + − ⋅ ⋅ ⋅ ⋅ + ⋅ 
. 
Thus, at the core of the analysis was a value model based on the expected value, with value 
computed as a weighted additive combination of health gain and inequality reduction.  There is 
precedent for this sort of modelling strategy in the decision analysis literature: for example, 
Keeney and Winkler (1985) also present an additive model with absolute and distributional 
components for evaluating risk reductions.  
 
Third, participants were presented with a triangle that focused the discussion on Value-for-Money 
of each intervention (Figure 2). The horizontal side of the triangle is the additional cost cj 
associated with the intervention; the vertical side is the additional expected benefit score E(vj); 
and the slope of the hypotenuse of the triangle represents Value-for-Money with steeper 
hypotenuses representing better value for money, that is, more benefits for each pound spent. 
Showing the triangles stimulated a discussion both for their comparative size and slope. In most 
cases participants recognised the comparison as a fair representation of their intuitive judgments, 
but they had now a language to entertain a more informed discussion. In few cases results were 
less intuitive and explored extensively by revising the assessments of costs and benefits that 
constituted the scale and slope of the triangle creating a better understanding of the appraised 
interventions. Whenever necessary, assessments were revised. 
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Figure 2 The structure of a value-for-money triangle 
 
Results 
The triangles were used to generate a priority list in which interventions were ranked according to 
Value-for-Money (Table 2), from the triangle with the steepest hypotenuse to the one with the 
flattest. This ranking is a cost effectiveness ranking similar to cost/QALY league table. Extensive 
sensitivity analysis was used to explore the uncertainties and disagreements among participants 
and the model proved robust.  Figure 3 shows the same information in graphical form.  The visual 
display generated important learning: for example, one intervention the evaluation of which had 
attracted considerable attention within the organisation, was represented by a triangle which was 
not only shallow (and thus low value for money), but tiny, because they it touched such a small 
number of people.  Thus, from the point of view of almost everyone in the local population, and 
from the point of view the cost imposed on the system, it did not really matter whether this 
intervention was undertaken or not. To our minds, this sort of insight validates the importance of 
looking at benefits scaled up to the level of the population. 
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Table 2 Priority order according to Value-for-money (‘league table’) for k=0.5. 
Commissioning 
area [g] 
Intervention 
[j] 
Additional 
cost in £k 
[cj] 
Additional 
benefit 
[E(vj)] 
VfM 
ratio 
[E(vj)/cj] 
 
Cumulative 
cost in £k 
Cumulative 
benefit 
RESPIRATORY pneumonia  £           75           11.84         0.1579   £           75           11.84  
MENTAL 
HEALTH 
Dementia 
services  £           50             5.18         0.1036   £         125           17.02  
CVD TIA & 2ndary prevention  £         130             5.40         0.0415   £         255           22.42  
MENTAL 
HEALTH Prison MH  £         150             4.51         0.0301   £         405           26.94  
CHILDREN Obesity training  £           60             1.73         0.0289   £         465           28.67  
CHILDREN Workforce development  £         100             2.78         0.0278   £         565           31.44  
MENTAL 
HEALTH Psych therapies  £         120             3.05         0.0254   £         685           34.49  
CANCER Early detection 
and  diagnostics  £         300             5.74         0.0191   £         985           40.23  
CHILDREN CAMHS School  £         160             2.76         0.0173   £      1,145           42.99  
CVD Prevention  £         650           10.48         0.0161   £      1,795           53.48  
CHILDREN CAMHS 1:1  £           80             1.26         0.0157   £      1,875           54.73  
CVD Cardiac Rehab  £         100             1.29         0.0129   £      1,975           56.02  
MENTAL 
HEALTH 
Alcohol misuse 
svc 
 £         300             3.77         0.0126   £      2,275           59.78  
MENTAL 
HEALTH Social inclusion  £         300             3.75         0.0125   £      2,575           63.54  
CANCER Palliative & EOL  £         760             9.05         0.0119   £      3,335           72.59  
CHILDREN Obesity 1:1  £         140             1.22         0.0087   £      3,475           73.81  
CHILDREN Primary prevention  £         600             4.61         0.0077   £      4,075           78.42  
CHILDREN Access to dental  £         480             3.24         0.0068   £      4,555           81.66  
CANCER Active Treatment  £           50             0.31         0.0062   £      4,605           81.97  
CVD Stroke 
emergency  £         600             3.37         0.0056   £      5,205           85.34  
CVD CHD acute  £         300             0.78         0.0026   £      5,505           86.12  
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Figure 3 The efficient frontier of triangles ranked by value-for-money 
 
 
Three weeks after the Decision Conference, participants received a copy of the report for 
consultation. The report summarised the approach, documented each step of the process, and the 
results of the base models and of sensitivity analyses. The executive directors and commissioning 
leads discussed the results and proposed an operational plan based on the analysis to the IoW 
NHS Board for approval. The proposal followed the VfM ranking of Table 2 and Figure 3 with 
the exception of End of Life care for which separate funding was provided in addition to the 
planned £1m. 
 
The IoW NHS Board received the results of the analysis favourably and approved the proposed 
operational plan. The Board found the efficient frontier (Figure 3) particularly insightful (JS 
attended the meeting). It enabled them to visualise the expected efficiency gain of about 25% 
compared to the alternative ranking and to articulate a clear rationale for the proposed list of 
interventions based on the principles of opportunity cost.  In the end, the PCT Board approved an 
operational plan to fund the interventions with the highest Value-for-Money as resulting from the 
analysis, with the exception of the End of Life proposal which was funded irrespective of the 
analysis. 
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The following year, 2009, the PCT hired a private consultancy firm of trained decision analysts 
able to replicate the approach and participants from the previous year confirmed their willingness 
to engage in the workshops, which were extended to more people.  Thus the approach which we 
introduced was seen as adding value, and had momentum.  However, following the structural 
reforms announced by the coalition government in 2010, the Primary Care Trust tier of the NHS 
is to be abolished.  At the time of writing it is unclear where healthcare planning will sit in the 
English system and what form it will take.  
4.  Discussion 
Accessibility 
The approach was relatively accessible to the Strategic planning group. This is not surprising 
because they had been continuously and actively engaged in designing the framework and the 
elicitation frameworks used were based on their conscious and deliberate choice. For instance, in 
the design of a scoring procedure the group first considered the use of “fixed scales” to provide a 
qualitative description of different levels on the scale of each criterion (Bana e Costa & Beinat, 
2005), but the Strategic planning group considered this too laborious to develop and too difficult 
for invited participants to understand. The group proposed to use a simple scoring tool of ‘High- 
Medium- or Low- impact’ which was not ultimately used because it might not have been 
sufficient to discriminate among alternatives and it would have been difficult to ensure 
consistency in scoring alternatives which fell on the border of two categories. Further, in 
preparation for the prioritisation event with stakeholders of the six commissioning areas the 
Strategic planning group pilot-tested the proposed scoring tools in a mock Decision Conference 
for a sample of interventions. The pilot proved useful to test the accessibility of the visual aids, 
and to improve the definition of feasibility in terms of ‘probability of success’ to replace the 
original definition in terms of ‘ease of implementation’, a concept which proved unhelpful 
whenever participants held different views because each participant seemed to hold a different 
perception of ‘ease’.  
 
The use of the decision analytic principles with the development of simple visual aids for each 
step of the process proved invaluable in the deliberative process with the invited stakeholders, and 
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participants particularly praised the quality of the discussion the framework enabled before, 
during and after the event. Before the event, the framework defined specific questions and 
focused the data extraction. During the event, the use of rectangles to visualise the population 
health gain helped clinicians and patients to share their knowledge or to articulate their expert 
opinion on the impact for the individual patient; and it enabled participants to advise 
commissioning leads more clearly on the details of the implementation to achieve a larger number 
of beneficiaries, the associated costs, and to document the agreed changes. This was particularly 
evident for interventions in primary prevention, for which hard evidence was not available and 
local characteristics of the health economy are particularly critical: it enabled participants to 
volunteer estimates and for these to be challenged by others.  
 
Similarly, the triangles of Value-for-Money and their aggregation in an efficient frontier enabled 
participants to engage in a discussion on the opportunity cost of alternative budget allocations 
both during and after the event. In particular, participants tested the impact of alternative scores 
and weights on the efficiency frontier as well as the opportunity cost of financing an alternative 
with relatively low VfM, by exploring what options would have to be given up if that alternative 
were to be funded. 
 
At the merge meeting it became evident, however, that our definition of health inequalities was 
not as accessible as we would have liked. In particular, if health inequalities are measured in 
terms of the health gap between different groups in the population measured for instance in terms 
of quality-adjusted life expectancy at birth, one would expect that the higher the number of 
health-poor people affected the higher the impact on health inequalities. Participants, however, 
did not consider the number of people affected by the intervention unless prompted by the 
facilitators and the rationales used to defend their health inequality score usually reflected their 
personal view of the extent of “health-poverty” of a typical beneficiary or his/her deservingness 
of better health.  The development of a more intuitive and theory-based approach to modelling 
health inequality is the focus of ongoing research (Morton & Airoldi, 2010). 
Acceptability 
With the exception of one member, members of the Strategic planning group found the approach 
acceptable in terms of the included criteria, their definition, their operationalisation, and the 
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method to translate values into a priority order and the evaluation of palliative and end of life 
treatments. 
 
The objecting member of the Strategic planning group raised a general concern with the use of 
“an approach which aims at getting the greatest good for the greatest number”. This was clearly a 
rejection of the utilitarian principle embedded in the ‘a QALY is a QALY is a QALY’ principle 
commonly applied in health economics. At the core of the objection was a legalistic and 
pragmatic perspective and she contended that it would have been difficult to defend hard choices 
based on the utilitarian principle in front of the public or the courts. The majority of the Strategic 
planning group, however, thought that the utilitarian principle was acceptable and would have 
been useful to identify the hard trade-off involved in funding decisions; they agreed to aggregate 
health gains across people additively in the analysis and to discuss the political feasibility of the 
recommended set of interventions to be funded at the end of the process. 
 
For the specific assessment of palliative and end of life interventions the executive directors and 
commissioning leads judged the approach unacceptable and decided to ignore the results for these 
treatments. They felt that the value of these interventions is to provide ‘a good death’ and this 
could not be captured by the criteria used in the approach. They were not able to articulate a 
general, acceptable definition of ‘good death’ as different patients and their families may have 
very different needs at this difficult time of their life and ‘a good death’ may have more to do 
with allowing them time to understand these needs and respecting their wishes than with a 
specific healthcare intervention (Sandman, 2005).  
 
The difficulty of using a common tool to assess curative and palliative interventions is not unique 
to this case study, as demonstrated by the debate about the appropriate cost-effectiveness 
threshold within the cost per QALY approach for end of life treatments, in which some authors 
advocate for the appropriateness of a higher cost per QALY threshold (Mason, Jones-Lee, & 
Donaldson, 2009; Towse, 2009). The recent report on End of Life issued by the National Audit 
Office in the UK, which assess the Value-for-Money of public services, has also sidestepped the 
issue of attaching a value to treatment and focused its analysis on costs (National Audit Office, 
2008). 
 
The assessment of preventative and potentially life-saving interventions posed a similar 
challenge, with participants invoking the ‘rule of rescue’ principle – the moral imperative to 
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rescue identified people in immediate peril regardless of the costs – to express their difficulty in 
comparing the relative health benefits across these interventions. The executive directors decided 
to exclude ‘rule of rescue’ considerations in the formal analysis in order to be able to quantify and 
to face the hard trade-offs between investing in prevention compared to treatment. They 
recognised that the choice between prevention and potential cure is an intrinsically difficult value 
judgment but also highlighted the value of visualising the opportunity cost of providing additional 
treatment to inform their decisions. Their difficulty is consistent with the current absence of any 
clear, agreed operationalisation of the rule of rescue principles (Cookson, McCabe, & Tsuchiya, 
2008). Despite the dismissal of ‘rule of rescue’ considerations, however, the analysis identified 
most preventative interventions as poor Value for Money because they were usually also 
associated with a relatively low probability of success (which reduced their expected value). 
 
Most clinicians and patients appreciated the logic of the approach but were somewhat 
uncomfortable with the use of subjective estimates to assess interventions. For instance, clinicians 
played a crucial role to assess the health benefit to the average patient. They volunteered their 
estimates based on their knowledge of the literature and their professional expertise and found the 
process acceptable to stimulate a discussion but frequently called for a more systematic use of the 
evidence to validate their judgments. In particular, they found it difficult to assess the relative 
health gain from different interventions for the ‘average’ beneficiaries as they felt that in their 
professional experience “there is no such thing as an ‘average’ patient” and their professional 
ethos demanded “to do the best [they] could possibly do for each individual patient”. 
 
Similarly, one of the patient representatives highlighted that he enjoyed the event and that the 
process was “an advance on just sitting around a table and talking it through”, but that he was 
uneasy about the subjectivity of the estimates. He was not convinced that extensive sensitivity 
analyses could replace objective evidence and invited the PCT to collect more objective 
epidemiological and clinical evidence, and to use it to put into perspective the anecdotal evidence 
that the public is most likely to draw upon. 
 
The executive directors recognised that several estimates were based on expert judgments brought 
to bear on the day and discussed their confidence in the model results. They concluded that the 
model was a fair representation of the evidence available on the day, the knowledge shared by 
those who participated in the event but appreciated that a different group of participants and the 
collection of more evidence might have led to different results. This naturally raised questions 
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which were dealt with extensive sensitivity analysis on scores and weights to assess in particular 
the robustness of the model to different assumption on the effectiveness (numbers who benefits 
and benefit per person) of preventative interventions. The model proved robust to extreme 
changes in scores and weights, which increased the confidence of the executive team to base the 
recommendations for funding on the results of the model.   
5.  Conclusions 
This paper describes a socio-technical approach to bring together those responsible for allocating 
resources to healthcare intervention on behalf of a local population with different sources of 
expert knowledge to inform their decision. It presents a framework for prioritisation, comprising a 
value model, a communication procedure and an interactive elicitation method to enable 
participants in articulating their views, communicating and sharing their expertise and 
formulating their value judgments through a weighting a scoring procedure supported by simple 
visual aids.   The interactive engagement with those responsible to recommend a plan for resource 
allocation in designing the approach contributed to its accessibility and acceptability. The results 
of the work had a material and demonstrable influence on spending decisions by the PCT.  
 
The framework that we present draws explicitly on health economics.  As such it provides a 
framework within which evidence from public health and demographic surveys, health economic 
studies and RCTs, and local administrative and accounting systems can be synthesised with the 
judgement of the people who know the system best, and structured to be directly relevant to 
management decisions.  We believe our success in facilitating clear, value-driven and evidence-
based discussions are attributable to the intellectual robustness of the underpinning health 
economic theory, and indeed, where our methods were less informed by health economics – as in 
the modelling of inequality, and the health benefit/ inequality tradeoff – we were less successful 
in facilitating such discussions.   
 
This notwithstanding, the approach we present is genuinely a sociotechnical one, which aims to 
enable discussion and reflection rather than prescribe choice.  Hence, in areas where health 
economics theory has less purchase as a normative theory– in particular in the valuation of End of 
Life care – decision makers set aside the priorities as assessed by the model and, for explicit and 
legitimate reasons, made their decisions on the basis of other concerns.  This is of course as it 
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should be, for in an arena where values are as contested as healthcare, the highest aspiration for 
analysis can only be to provide a basis for thoughtful and informed moral choices. 
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